Man Group
URGN icon

Man Group’s UroGen Pharma URGN Stock Holding History

Man Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,395
Closed -$457K – 2626
2026
Q1 		$457K Buy
+25,395
New +$509K ﹤0.01% 2113
2025
Q4 		– Sell
-10,780
Closed -$215K – 2484
2025
Q3 		$215K Sell
10,780
-3,505
-25% -$62.9K ﹤0.01% 2091
2025
Q2 		$196K Buy
+14,285
New +$137K ﹤0.01% 2077
2023
Q1 		– Sell
-14,300
Closed -$132K – 1879
2022
Q4 		$127K Buy
+14,300
New +$135K ﹤0.01% 1872
2019
Q3 		– Sell
-16,484
Closed -$592K – 1920
2019
Q2 		$592K Sell
16,484
-162,512
-91% -$5.99M ﹤0.01% 1638
2019
Q1 		$6.61M Buy
178,996
+59,260
+49% +$2.48M 0.03% 766
2018
Q4 		$5.16M Buy
119,736
+13,188
+12% +$593K 0.02% 753
2018
Q3 		$5.03M Buy
106,548
+85,416
+404% +$3.97M 0.02% 992
2018
Q2 		$1.05M Buy
+21,132
New +$1.23M ﹤0.01% 1595

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Man Group's URGN Position: Q2 2026 in Review

Man Group sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 25,395 shares — an estimated $457K sold.

Man Group first reported a position in URGN in Q2 2018 and held it in 9 quarters. The position peaked at $6.61M in Q1 2019. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Man Group reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
  • Man Group sold 25,395 UroGen Pharma shares in Q2 2026, an estimated $457K.
  • Man Group first reported a position in UroGen Pharma in Q2 2018 and held it in 9 quarters.
  • Man Group's UroGen Pharma position peaked at $6.61M in Q1 2019.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.